1. Scrip
  2. >>Therapy Areas

Asia Beat: Business trumping politics in cross-strait thaw?

 
• By Ian Haydock

Given their intertwined history and culture, the People's Republic of China and the large island to its east would seem to have a lot in common. But while the political gulf with Taiwan will not be easily bridged, recent cross-strait activity suggests that shared interests in the healthcare sector are at least partly overcoming ideological differences.

Given their intertwined history and culture, the People's Republic of China and the large island to its east would seem to have a lot in common. But while the political gulf with Taiwan will not be easily bridged, recent cross-strait activity suggests that shared interests in the healthcare sector are at least partly overcoming ideological differences.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapeutic Category

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.